Analyse produit facultative
Avec votre autorisation, nous utilisons une analyse limitée et respectueuse de la vie privée pour comprendre les parcours de recherche utiles. Nous n’utilisons ni traceurs publicitaires ni enregistrement de session. Vous pouvez modifier ce choix dans les préférences. Consultez la Politique de confidentialité.
HCA Healthcare Inc.'s published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $101.9B | |
|---|---|---|
| P/E (forward) | 13.8x |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $58.75B | $60.23B | $64.97B | $70.60B | $75.60B | +6.5% |
| Gross profit | $22.49B | $23.18B | $25.58B | $28.68B | $31.37B | +8.7% |
| Operating income | $11.40B | $10.32B | $9.64B | $10.58B | $12.08B | +1.5% |
| Net income | $6.96B | $5.64B | $5.24B | $5.76B | $6.78B | -0.6% |
| EPS (diluted) | $21.16 | $19.15 | $18.97 | $22.00 | $28.33 | +7.6% |
| EBITDA | $14.25B | $13.29B | $12.72B | $13.90B | $15.60B | +2.3% |
| R&D | — | — | — | — | — | — |
| SG&A | $26.78B | $27.69B | $29.49B | $31.17B | $8.00B | -26.1% |
Recent company headlines from major financial publishers.
The modal path reflects steady same-facility equivalent admission expansion supported by favorable Sunbelt demographic trends, tempered by gradual outpatient procedure migration. Operating margins remain stable as purchasing efficiencies through the group purchasing organization balance clinical wage pressures, while regular share repurchases funded by operational cash conversion drive compound per-share growth.
Under the upside trajectory, rapid demographic expansion in key Sunbelt metropolitan markets drives accelerated commercial admissions and a rebound in higher-acuity inpatient surgical procedures. Centralized purchasing scale and clinical workflow productivity contain operating expense inflation, expanding operating margins and enabling robust free cash flow to accelerate share repurchase execution.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 8.3% | $557 | $578 | $602 | $629 | $660 |
| 8.8% | $513 | $530 | $548 | $569 | $592 |
| 9.3% | $476 | $490 | $504 | $521 | $539 |
| 9.8% | $445 | $456 | $468 | $482 | $496 |
| 10.3% | $419 | $428 | $438 | $449 | $461 |
Upcoming earnings date and setup when available.
La notation portée par l'édition de recherche publiée chaque mois. Une notation compare le cours à la date d'analyse à la juste valeur ; elle n'indique pas si l'appréciation s'est révélée juste.
| Année | janv. | févr. | mars | avr. | mai | juin | juil. | août | sept. | oct. | nov. | déc. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
